Navigation Links
ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009

RANCHO CORDOVA, Calif., Jan. 29 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal second quarter ended December 31, 2008, on Wednesday, February 4, 2009.

Company's Conference Call and Webcast

Management will host a conference call Wednesday, February 4, 2009 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal second quarter financial results.

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1- 412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Mr. Matthew Plavan, Chief Executive Officer will host the call to discuss the second quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.

To listen to the audio webcast of the call during or after the event, please visit:


A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

     ThermoGenesis Corp.
     Web site:
     Contact: Investor Relations
     1-916-858-5107, or

SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ThermoGenesis Presentation at Rodman & Renshaw Conference
2. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
3. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
6. ThermoGenesis Names Tiffany Olson to Board of Directors
7. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
8. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
11. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... Paris Police Prefecture ... solution to ensure the safety of people and operations in ... major tournament Teleste, an international technology group specialised ... today that its video security solution will be utilised by ... public safety across the country. The system roll-out is scheduled ...
Breaking Biology News(10 mins):